{"product_id":"rxrx-pestle-analysis","title":"(RXRX) Recursion Pharmaceuticals, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Recursion Pharmaceuticals, Inc. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces affect the company and is useful for investors, strategists, and researchers. The page includes a real preview\/sample of the analysis so you can judge style and depth before buying; purchase the full report to access the complete, ready-to-use version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS FDA clinical oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. depends on U.S. FDA review, trial authorization, and safety reporting for its 4 clinical-stage programs, including REC-994, REC-3599, REC-2282, and REC-4881. Any delay in Phase I or Phase IIa decisions can push back rare-disease timelines, where patient pools are small and each site or protocol change matters more. That makes FDA engagement a core political risk, not a side issue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUtah headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is based in Salt Lake City, so it benefits from Utah’s life-science support, talent pool, and local policy links. Utah’s low-tax, pro-business setup can affect hiring, site growth, and operating costs, while the Salt Lake life-science cluster can improve access to partners, labs, and suppliers. In 2025, that mix still matters because Recursion is scaling in a state where policy and clustering can shape speed, cost, and recruitment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCross-border partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. works with Bayer AG and Takeda Pharmaceutical Company Limited, so it faces policy and trade rules in Germany, Japan, and the U.S. Cross-border deals can widen funding and development reach, but they also add approval, governance, and data-transfer friction. In 2025, trade and export-control shocks still threaten trial inputs and project timing across these markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease policy support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. has several programs in rare and ultra-rare diseases, including cerebral cavernous malformation, GM2 gangliosidosis, and neurofibromatosis type 2. That matters because orphan-drug policy can speed review and grant U.S. market exclusivity for 7 years, while the EU offers 10 years, which supports pricing power and lowers launch risk.\u003c\/p\u003e\n\u003cp\u003eThis policy backdrop is central to the pipeline’s commercial case: rare-disease drugs can qualify for tax credits, fee waivers, and priority pathways, which can cut development friction and improve capital efficiency. For Recursion Pharmaceuticals, Inc., the political case is strongest when regulators keep orphan incentives stable and predictable.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e7-year U.S. orphan exclusivity\u003c\/li\u003e\n\u003cli\u003e10-year EU orphan exclusivity\u003c\/li\u003e\n\u003cli\u003eFaster review can aid launch timing\u003c\/li\u003e\n\u003cli\u003ePolicy support underpins pipeline value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare spending policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUS public and private payer rules shape Recursion Pharmaceuticals, Inc.'s future access and reimbursement, especially for oncology and rare-disease drugs. In the US, health spending reached $4.9 trillion in 2023, and CMS will begin IRA price negotiations for 10 high-spend drugs in 2026, showing how policy can move long-term value even before approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage rules can lift or block uptake.\u003c\/li\u003e\n\u003cli\u003ePricing policy hits high-cost therapies hardest.\u003c\/li\u003e\n\u003cli\u003eReimbursement risk matters before launch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and CMS Policy Could Shift Recursion’s Launch Timelines and Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk for Recursion Pharmaceuticals, Inc. is mostly U.S. FDA and CMS policy: one late review or pricing rule can shift rare-disease launch timing and margins. Orphan-drug incentives still matter, with 7-year U.S. exclusivity and 10-year EU exclusivity supporting pipeline value. Cross-border ties with Bayer AG and Takeda Pharmaceutical Company Limited also expose the Company to trade, data, and approval rules.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolicy\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. orphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU orphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e10 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS IRA talks\u003c\/td\u003e\n\u003ctd\u003e10 drugs in 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExamines how political, economic, social, technological, environmental, and legal forces shape Recursion Pharmaceuticals, Inc.’s strategy, risk, and growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, structured Recursion Pharmaceuticals PESTLE summary that simplifies external risk review and supports faster strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary authoritative sources—peer‑reviewed studies, SEC filings, industry reports, and clinical registries—so investors can quickly verify Recursion’s market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage, no approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. remained a pre-commercial company in FY2025, with no approved products and no product-sales revenue stream. That leaves revenue tied to collaborations, milestones, and financing, while R\u0026amp;D and SG\u0026amp;A cash burn stays high; the company still posted a net loss, so funding risk remains a key economic pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is running 4 clinical-stage programs plus multiple preclinical assets, so R\u0026amp;D spend stays high. In biotech, trials, data sets, lab automation, and wet-lab ops can push annual cash burn into the hundreds of millions, making capital discipline critical. That spending pressure can shape how fast the pipeline moves and how long the balance sheet lasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-funded development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. reduces R\u0026amp;D burn through partner-funded work: its Bayer and Takeda alliances, plus academic foundation grants, can bring upfront cash, research support, and milestone-based revenue. The Bayer deal was expanded to up to $1.2 billion in potential biobucks, while the Takeda pact added up to $1.2 billion more. That mix lowers dependence on equity markets and helps fund longer programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital market sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is still a development-stage biotech, so it depends on equity markets for funding. With the U.S. policy rate at 5.25%-5.50%, higher discount rates can lift capital costs and make new equity less attractive. If biotech sentiment stays weak, share-price swings can limit deal timing and reduce strategic flexibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEquity funding matters most.\u003c\/li\u003e\n\u003cli\u003eHigh rates raise capital costs.\u003c\/li\u003e\n\u003cli\u003eVolatility can block strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease pricing potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-994 and REC-3599 sit in rare-disease markets, where even a small patient pool can support six-figure annual pricing if clinical benefit is clear. That can lift revenue per patient fast, but total upside stays capped by limited prevalence.\u003c\/p\u003e\n\u003cp\u003ePayer pushback is the real test: coverage improves when evidence is strong, and weak data can quickly force discounts or access limits. In orphan drugs, premium pricing often works only when outcomes are durable and hard to replace.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall pools, high price potential\u003c\/li\u003e\n\u003cli\u003eProof of efficacy drives payer access\u003c\/li\u003e\n\u003cli\u003eLimited prevalence caps total revenue\u003c\/li\u003e\n\u003cli\u003eWeak evidence can cut returns fast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion’s Biggest Risk: Funding in a Tough Biotech Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. remains cash-burning in FY2025, so funding access is the core economic risk. Partner cash from Bayer and Takeda can offset some R\u0026amp;D spend, but higher rates and weak biotech markets still raise dilution risk and cost of capital.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBayer potential\u003c\/td\u003e\n\u003ctd\u003eup to $1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTakeda potential\u003c\/td\u003e\n\u003ctd\u003eup to $1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBusiness model\u003c\/td\u003e\n\u003ctd\u003epre-commercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eRecursion Pharmaceuticals, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis of Recursion Pharmaceuticals, Inc. you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning or investor review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnmet need in rare disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRare disease care has a strong unmet-need signal: about 300 million people worldwide live with one of more than 7,000 rare diseases, and most have no approved treatment. Recursion Pharmaceuticals, Inc. targets severe neurologic and genetic disorders, where patients and caregivers often join trials quickly when options are absent. Clear clinical benefit can also speed later uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRare-disease advocacy matters for Recursion Pharmaceuticals, Inc. because patient groups help surface symptoms, speed diagnosis, and boost trial enrollment; about 300 million people live with a rare disease worldwide, and over 90% have no approved treatment. Advocacy networks can also lift research visibility and push funders and regulators for faster access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. targets severe neurologic diseases such as cerebral cavernous malformation, GM2 gangliosidosis, and neurofibromatosis type 2, all of which can drive lifelong disability and heavy caregiver strain. Neurologic disorders are a major global burden: the 2021 Global Burden of Disease study counted 3.4 billion people living with nervous system conditions worldwide. That scale of lost function and quality of life supports demand for effective therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology unmet need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCancer’s social burden stays high: GLOBOCAN estimates about 20 million new cases and 9.7 million deaths in 2022, and many patients still face relapse after standard therapy. That is why REC-4881, REC-65029, REC-2029, REC-14221, and REC-64151 matter: they target hard-to-treat oncology settings where patients and clinicians strongly seek new options.\u003c\/p\u003e\n\u003cp\u003eFor Recursion Pharmaceuticals, Inc., this unmet need supports demand for differentiated treatments, especially after first-line failure. In one line: when current care stops working, willingness to try novel cancer drugs rises fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20M new cancer cases in 2022\u003c\/li\u003e\n\u003cli\u003e9.7M cancer deaths in 2022\u003c\/li\u003e\n\u003cli\u003eHigh relapse drives social demand\u003c\/li\u003e\n\u003cli\u003eTargets focus on resistant disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrust in data-driven drug discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrust is central for Recursion Pharmaceuticals, Inc. because its platform blends biology, chemistry, automation, data science, and engineering. As AI-enabled discovery becomes more accepted, credibility can rise with researchers, partners, and investors, which matters when the Company moves novel candidates into trials.\u003c\/p\u003e\n\u003cp\u003ePublic trust also depends on proof: clear data, reproducible results, and safety signals. In 2025, the global AI-in-drug-discovery market was valued in the low single-digit billions and is still expanding fast, so Recursion’s reputation can move with broader confidence in data-led science.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrust supports partner and investor confidence.\u003c\/li\u003e\n\u003cli\u003eTrial-stage candidates need public credibility.\u003c\/li\u003e\n\u003cli\u003eAI acceptance can lift research buy-in.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease and Cancer Demand Fuel Recursion's Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. benefits from strong rare-disease and cancer patient demand: about 300 million people live with a rare disease, over 90% have no approved treatment, and GLOBOCAN counted 20 million new cancer cases and 9.7 million deaths in 2022. Patient groups, caregivers, and advocates can speed diagnosis, trial enrollment, and acceptance of new therapies. Trust still depends on clear safety and proof.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease\u003c\/td\u003e\n\u003ctd\u003e300M people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo approved treatment\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer burden\u003c\/td\u003e\n\u003ctd\u003e20M cases, 9.7M deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated discovery platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion’s integrated discovery platform links biology, chemistry, automation, data science, and engineering in one workflow, which helps it move faster than a traditional wet-lab model. The company says its platform has built more than 65 petabytes of proprietary biological and chemical data, giving it scale in target ID and lead generation. That data-heavy setup is a key edge in 2025\/2026 drug discovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomation and high-throughput systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.'s model depends on automated labs and high-throughput screens to generate large biological data sets fast. That setup can improve reproducibility and cut discovery cycle time, but it also means the company must keep spending on robots, software, and system upkeep. With R\u0026amp;D still the main cost driver in FY2025, automation is both an edge and a fixed cash drain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical pipeline breadth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. has 4 clinical-stage compounds: REC-994, REC-3599, REC-2282, and REC-4881. That breadth spreads technical risk across different mechanisms and indications, instead of relying on one asset. It also gives multiple readouts to test whether the platform is translating into human data, which matters as the company advances into 2025-2026 clinical milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePreclinical portfolio depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. reports at least 7 preclinical candidates, including REC-3964, REC-64917, REC-65029, REC-648918, REC-2029, REC-14221, and REC-64151. That depth gives it more shots on goal if an early program stalls or fails, which matters in a pipeline-driven biotech model.\u003c\/p\u003e\n\u003cp\u003eIt also raises the load on data generation, since each asset needs preclinical evidence before clinical filing. In 2025\/2026 filings, Recursion Pharmaceuticals, Inc. still showed no product revenue, so pipeline output remains the key value driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e7+ preclinical assets support renewal\u003c\/li\u003e\n\u003cli\u003eMore assets mean more data work\u003c\/li\u003e\n\u003cli\u003ePipeline progress drives value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExternal research collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.'s partnerships with Bayer, Takeda, the University of Utah Research Foundation, the Ohio State Innovation Foundation, and Chromaderm widen access to disease know-how, discovery tools, and validation paths. That matters because external collaborators can split scientific and development risk while adding scale to a platform that still held $310.4 million in cash, cash equivalents, and short-term investments at Dec. 31, 2024.\u003c\/p\u003e\n\u003cp\u003eThese links also support faster target testing and broader biology coverage, which can improve hit rates in early drug discovery. In a capital-heavy field, shared research can lower the cost of learning before bigger clinical bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader technical access\u003c\/li\u003e\n\u003cli\u003eAdded disease expertise\u003c\/li\u003e\n\u003cli\u003eShared R\u0026amp;D risk\u003c\/li\u003e\n\u003cli\u003eMore validation options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion’s AI Drug Discovery Engine Is Scaling—But Burns Cash Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.’s tech edge is its AI-led, automated discovery platform, backed by 65+ petabytes of proprietary data and 4 clinical-stage plus 7+ preclinical programs. That scale can speed target finding and improve hit rates, but it also keeps R\u0026amp;D and lab automation costs high. Cash, cash equivalents, and short-term investments were $310.4 million at Dec. 31, 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary data\u003c\/td\u003e\n\u003ctd\u003e65+ petabytes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical-stage compounds\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical candidates\u003c\/td\u003e\n\u003ctd\u003e7+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and investments\u003c\/td\u003e\n\u003ctd\u003e$310.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. must keep every clinical program aligned with U.S. FDA rules on protocol design, safety checks, and trial reporting. Phase I and Phase IIa studies also need strict human-subject protections under GCP, and any breach can delay, suspend, or end development. That matters for cash burn too: a single hold can push trial timelines back by months and raise R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech value rests on patents, know-how, and exclusive licenses; U.S. utility patents usually last 20 years from filing. Recursion Pharmaceuticals, Inc. needs strong IP around its platform and pipeline to protect future drug launches and partner talks. Weak patent coverage or an IP dispute would cut its edge and weaken pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration contract obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.’s Bayer and Takeda deals, plus academic foundation ties, create binding duties on milestones, confidentiality, and data rights, so contract wording can decide who owns new targets and how cash is split. These agreements often gate revenue through milestone and royalty terms, and Recursion’s latest filings still show collaboration income as a core funding source, not just a side line. Clear IP language matters because one disputed assay result can block downstream licensing, delay commercialization, and weaken partner trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData privacy and security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. handles sensitive biological and partner data, so privacy and cyber controls shape how it stores, transfers, and shares research files. A breach could trigger legal claims, regulatory scrutiny, and loss of partner trust, which matters in a business built on external collaborations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtects clinical and research data\u003c\/li\u003e\n\u003cli\u003eControls partner data sharing rules\u003c\/li\u003e\n\u003cli\u003eReduces breach and liability risk\u003c\/li\u003e\n\u003cli\u003eSupports partner confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGxP and quality systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. must keep GCP and GLP tight across its multi-asset pipeline so trial data stay valid, lab results stay reproducible, and FDA submissions hold up. In 2025, the company still ran a broad discovery and clinical engine, so quality failures could hit several programs at once. Strong QMS controls are a legal need, not a nice-to-have.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGCP protects trial integrity.\u003c\/li\u003e\n\u003cli\u003eGLP supports lab data reliability.\u003c\/li\u003e\n\u003cli\u003eQMS lowers multi-program risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion's legal risks could delay trials, raise burn, and impact IP value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. faces tight legal control on FDA, GCP, and GLP compliance, and any trial hold can delay programs and lift cash burn. Its IP and licensing terms are key, since U.S. patents last 20 years from filing and partner deals can shift target rights, milestones, and royalties. Privacy and cyber rules also matter because sensitive research data can trigger claims if mishandled.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent term\u003c\/td\u003e\n\u003ctd\u003e20 years from filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage risk\u003c\/td\u003e\n\u003ctd\u003eTrial hold can add months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData risk\u003c\/td\u003e\n\u003ctd\u003eBreach can trigger claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab energy use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech labs can use 5–10 times more energy per square foot than office space, mainly for HVAC, freezers, automation, and compute. Recursion Pharmaceuticals, Inc.’s AI-heavy discovery model likely pushes power use above a simple wet lab setup, so energy efficiency matters for both cost and ESG score. In 2025, U.S. electricity prices averaged about 17¢\/kWh, making every efficiency gain material.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiohazard and chemical waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDrug discovery at Recursion Pharmaceuticals, Inc. creates bio-samples, solvents, and reagents, so waste must be segregated, labeled, and disposed of under EPA and state rules. In 2025, EPA civil penalties for hazardous-waste violations reached up to about $70,000 per day per violation, so poor handling can get expensive fast. Waste controls also add facility cost, but they cut staff risk and inspection problems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. depends on lab consumables, specialized instruments, and outsourced materials, so its supply chain footprint is tied to how far and how often those inputs move. Transport and sourcing choices affect emissions, cost, and continuity; even one supplier delay can slow experiments and push out trial timelines. In 2025, that makes resilient, lower-carbon sourcing a direct operating risk, not just an ESG issue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate-related operating risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExtreme weather can still disrupt Recursion Pharmaceuticals, Inc.'s labs, shipping, and power supply, so time-sensitive experiments need backup plans and redundant vendors. Salt Lake City and partner sites face different risks, which can spread or concentrate downtime across the network. Business continuity planning matters because one missed run can delay data flows and push back model training and study timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeather can stop lab work and deliveries.\u003c\/li\u003e\n\u003cli\u003eSite risk differs by location.\u003c\/li\u003e\n\u003cli\u003eBackup systems protect research timing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSustainable R\u0026amp;D practices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.'s sustainable R\u0026amp;D use of AI can cut waste by lifting hit rates and avoiding repeated dead-end experiments, so fewer compounds and assays are needed per program. That matters for both cost control and ESG goals, since lower lab throughput usually means less consumable use and less rework.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigher hit rates mean fewer failed runs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBetter prediction can shrink assay counts.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLower waste supports ESG and margins.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion’s ESG Costs: Power, Waste, and Supply-Chain Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. faces high lab power use, waste-control costs, and supply-chain emissions, so energy and materials efficiency hit both margins and ESG. U.S. electricity averaged about 17¢\/kWh in 2025, and EPA hazardous-waste penalties can reach about $70,000 per day per violation. Weather and site outages can still delay runs, data, and trials.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePower\u003c\/td\u003e\n\u003ctd\u003e17¢\/kWh\u003c\/td\u003e\n\u003ctd\u003eHigher lab cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWaste\u003c\/td\u003e\n\u003ctd\u003e$70,000\/day\u003c\/td\u003e\n\u003ctd\u003ePenalty risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234978308361,"sku":"rxrx-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rxrx-pestle-analysis.webp?v=1785730670","url":"https:\/\/dcfanalyst.com\/products\/rxrx-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}